ASH 2023 | The unmet needs and future of CMML treatment
Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, outlines the current unmet needs in chronic myelomonocytic leukemia (CMML). While CMML is often grouped with myeloproliferative neoplasms (MPNs), more efforts should be focused on the specific needs and therapeutic goals of CMML alone to better combat its mutational burden. The standard hypomethylating agent (HMA) therapy is ineffective at combating the disease, meaning new therapies that can be combined with or replace HMAs (such as combinations with JAK inhibitors) are necessary for the future of CMML treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
